Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results
Neurocrine Biosciences (Nasdaq: NBIX) announced a conference call to discuss its 2021 fourth quarter and year-end financial results on February 11, 2022, at 5:00 a.m. PT (8:00 a.m. ET).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neurocrine Biosciences (Nasdaq: NBIX) announced a conference call to discuss its 2021 fourth quarter and year-end financial results on February 11, 2022, at 5:00 a.m. PT (8:00 a.m. ET). The press release will precede this at 4:30 a.m. PT. Investors can access the call via domestic (800-895-3361) and international (785-424-1062) dial-in numbers, using Conference ID: NBIX. A replay will be available on Neurocrine's website following the event, highlighting the company's commitment to addressing neurological and psychiatric disorders through its diverse portfolio and ongoing clinical programs.
Positive
- Scheduled conference call for Q4 and year-end 2021 financial results indicates transparency.
- Company's focus on life-changing treatments for serious disorders shows long-term growth potential.
Negative
- None.
Details
News Market Reaction – NBIX
The recorded move for NBIX in the trading session of this news was -0.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on Friday, February 11, 2022.
The schedule for the press release and conference call / webcast is as follows:
| February 11, 2022 at 4:30 a.m. PT / 7:30 a.m. ET |
| February 11, 2022 at 5:00 a.m. PT / 8:00 a.m. ET |
| 800-895-3361 |
| 785-424-1062 |
| NBIX |
The webcast can also be accessed on Neurocrine's website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2021-financial-results-301467978.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.